MDRNA, Inc. to Present at the 12th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference

BOTHELL, WA--(Marketwire - February 01, 2010) - MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that it will present at the 12th Annual BIO CEO & Investor Conference being held at the Waldorf Astoria Hotel in New York City, New York. J. Michael French, MDRNA’s President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs on Monday, February 8, 2010 at 1:00 p.m. (Eastern Time). Mr. French will also participate in a panel discussion on RNAi-based technology at 3:00 p.m. (Eastern Time) at the conference.

To access the live webcast of the MDRNA presentation, please visit the Investors section of the Company’s website at http://www.mdrnainc.com and go to the Event Calendar or click on the following link: http://www.veracast.com/webcasts/bio/ceoinvestor2010/48108103.cfm. Please allow time prior to the presentation to register and download any necessary software. A replay of the presentation will be available on the Investors section of the MDRNA website under Event Calendar approximately one hour after the live presentation and will be archived for three months. The RNAi-based technology panel discussion will not be webcast.

About the BIO CEO & Investor Conference

The BIO CEO & Investor Conference is the largest investor conference focused on the biotechnology industry. The conference provides a forum for public and private equity investors, research analysts, investment bankers and senior-level industry executives to learn about and discuss investment trends and investment opportunities in the biotechnology industry. For more information, visit www.ceo.bio.org.

About MDRNA, Inc.

MDRNA is a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). Our goal is to improve human health through the development of RNAi-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Over the past decade, we have developed substantial capabilities in molecular biology, cellular biology, lipid chemistry, peptide chemistry, pharmacology and bioinformatics, which we are applying to a wide range of RNAi technologies and delivery approaches. These capabilities plus the in-licensing of key RNAi-related intellectual property have rapidly enabled us to become a leading RNAi-based therapeutics company with a pre-clinical pipeline in oncology. Through our capabilities, expertise and know-how, we are incorporating multiple RNAi technologies as well as peptide- and lipid-based delivery approaches into a single integrated drug discovery platform that will be the engine for our clinical pipeline as well as a versatile platform for establishing broad therapeutic partnerships with biotechnology and pharmaceutical companies. We are also investing in new technologies that we expect to lead to safer and more effective RNAi-based therapeutics while aggressively building upon our broad and extensive intellectual property estate. By combining broad expertise in siRNA science with proven delivery platforms and a strong IP position, MDRNA is well positioned as a leading RNAi-based drug discovery and development company. Additional information about MDRNA, Inc. is available at http://www.mdrnainc.com.

MDRNA Forward-Looking Statements

Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of MDRNA to obtain additional funding; (ii) the ability of MDRNA to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of MDRNA and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of MDRNA and/or a partner to obtain required governmental approvals; and (v) the ability of MDRNA and/or a partner to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in MDRNA’s most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. MDRNA assumes no obligation to update and supplement forward-looking statements because of subsequent events.